| pubmed-article:12942567 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12942567 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:12942567 | lifeskim:mentions | umls-concept:C0079773 | lld:lifeskim |
| pubmed-article:12942567 | lifeskim:mentions | umls-concept:C1522690 | lld:lifeskim |
| pubmed-article:12942567 | lifeskim:mentions | umls-concept:C1096776 | lld:lifeskim |
| pubmed-article:12942567 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:12942567 | pubmed:dateCreated | 2003-8-27 | lld:pubmed |
| pubmed-article:12942567 | pubmed:abstractText | In single center studies and case reports, it was shown that pegylated liposomal doxorubicin (PEG-DOXO) was effective as second-line therapy for patients with cutaneous T-cell lymphoma (CTCL). The objective of this study was to evaluate the efficacy and toxicity of single-agent PEG-DOXO as second-line chemotherapy in patients with CTCL. | lld:pubmed |
| pubmed-article:12942567 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12942567 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12942567 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:12942567 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12942567 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12942567 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12942567 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12942567 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:12942567 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:12942567 | pubmed:author | pubmed-author:KnopfBurkhard... | lld:pubmed |
| pubmed-article:12942567 | pubmed:author | pubmed-author:DummerReinhar... | lld:pubmed |
| pubmed-article:12942567 | pubmed:author | pubmed-author:WollinaUweU | lld:pubmed |
| pubmed-article:12942567 | pubmed:author | pubmed-author:KonradHelgaH | lld:pubmed |
| pubmed-article:12942567 | pubmed:author | pubmed-author:BrockmeyerNor... | lld:pubmed |
| pubmed-article:12942567 | pubmed:author | pubmed-author:HauschildAxel... | lld:pubmed |
| pubmed-article:12942567 | pubmed:author | pubmed-author:KaatzMartinM | lld:pubmed |
| pubmed-article:12942567 | pubmed:author | pubmed-author:BuschJ-OJO | lld:pubmed |
| pubmed-article:12942567 | pubmed:author | pubmed-author:KochHans-Jürg... | lld:pubmed |
| pubmed-article:12942567 | pubmed:copyrightInfo | Copyright 2003 American Cancer Society. | lld:pubmed |
| pubmed-article:12942567 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12942567 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:12942567 | pubmed:volume | 98 | lld:pubmed |
| pubmed-article:12942567 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12942567 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12942567 | pubmed:pagination | 993-1001 | lld:pubmed |
| pubmed-article:12942567 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:12942567 | pubmed:meshHeading | pubmed-meshheading:12942567... | lld:pubmed |
| pubmed-article:12942567 | pubmed:meshHeading | pubmed-meshheading:12942567... | lld:pubmed |
| pubmed-article:12942567 | pubmed:meshHeading | pubmed-meshheading:12942567... | lld:pubmed |
| pubmed-article:12942567 | pubmed:meshHeading | pubmed-meshheading:12942567... | lld:pubmed |
| pubmed-article:12942567 | pubmed:meshHeading | pubmed-meshheading:12942567... | lld:pubmed |
| pubmed-article:12942567 | pubmed:meshHeading | pubmed-meshheading:12942567... | lld:pubmed |
| pubmed-article:12942567 | pubmed:meshHeading | pubmed-meshheading:12942567... | lld:pubmed |
| pubmed-article:12942567 | pubmed:meshHeading | pubmed-meshheading:12942567... | lld:pubmed |
| pubmed-article:12942567 | pubmed:meshHeading | pubmed-meshheading:12942567... | lld:pubmed |
| pubmed-article:12942567 | pubmed:meshHeading | pubmed-meshheading:12942567... | lld:pubmed |
| pubmed-article:12942567 | pubmed:meshHeading | pubmed-meshheading:12942567... | lld:pubmed |
| pubmed-article:12942567 | pubmed:meshHeading | pubmed-meshheading:12942567... | lld:pubmed |
| pubmed-article:12942567 | pubmed:meshHeading | pubmed-meshheading:12942567... | lld:pubmed |
| pubmed-article:12942567 | pubmed:meshHeading | pubmed-meshheading:12942567... | lld:pubmed |
| pubmed-article:12942567 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12942567 | pubmed:articleTitle | Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. | lld:pubmed |
| pubmed-article:12942567 | pubmed:affiliation | Department of Dermatology, Hospital Dresden-Friedrichstadt, Friedrichstrasse 41, 01067 Dresden, Germany. wollina-uw@khdf.de | lld:pubmed |
| pubmed-article:12942567 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12942567 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12942567 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12942567 | lld:pubmed |
